^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dilanubicel (DVX101)

    i
    Other names: DVX101, NLA101 , NLA 101
    Associations

    News

    Trials
    Company:
    Deverra Therapeutics
    Drug class:
    Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    3d
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=35, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 35 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    1m
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jun 2026 --> Oct 2026
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    6ms
    Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov)
    P2, N=1, Terminated, Fred Hutchinson Cancer Center | The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population & smaller # of enrolling sites, we were not able to reach accrual goals.
    Enrollment change • Trial termination
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    7ms
    Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov)
    P2, N=10, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Dec 2024 --> Jun 2024
    Trial primary completion date
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    10ms
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting | N=15 --> 20
    Enrollment open • Enrollment change
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    12ms
    Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov)
    P2, N=10, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Nov 2022 --> Dec 2024
    Trial primary completion date
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    1year
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    over1year
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Jun 2023 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    over2years
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=15, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Preclinical
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    over3years
    Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Fred Hutchinson Cancer Research Center | Trial completion date: Aug 2021 --> Jun 2025 | Trial primary completion date: Jan 2020 --> Jun 2023
    Clinical • Preclinical • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    fludarabine IV • thiotepa • Omisirge (omidubicel) • cyclophosphamide intravenous • dilanubicel (DVX101)